Literature DB >> 25624400

Rapid HIV progression during acute HIV-1 subtype C infection in a Mozambican patient with atypical seroconversion.

Cesar Velasco1, Erica Parker1, Lucia Pastor1, Abel Nhama1, Salesio Macuacua1, Inácio Mandomando1, Julià Blanco1, Denise Naniche2.   

Abstract

Acute human immunodeficiency virus (HIV) infection (AHI) refers to the period between viral transmission and development of an adaptive immune response to HIV antigens (seroconversion) usually lasting 6-8 weeks. Rare cases have been described in which HIV-infected patients fail to seroconvert and instead, develop rapid HIV-mediated clinical decline. We report the case of a Mozambican woman with AHI and malaria coinfection who showed atypical seroconversion and experienced rapid deterioration and death within 14 weeks of diagnosis with AHI. Atypical seroconversion may be associated with rapid progression. Fourth generation rapid tests could lead to earlier identification and intervention for this vulnerable subgroup. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Year:  2015        PMID: 25624400      PMCID: PMC4385758          DOI: 10.4269/ajtmh.14-0554

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  HIV-1 subtype C seronegative AIDS.

Authors:  Craig Corcoran; Diana Hardie
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 2.  Immunopathogenesis of HIV infection.

Authors:  G Pantaleo; A S Fauci
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

3.  Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts.

Authors:  N L Michael; A E Brown; R F Voigt; S S Frankel; J R Mascola; K S Brothers; M Louder; D L Birx; S A Cassol
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

4.  Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group.

Authors:  P S Sullivan; C Schable; W Koch; A N Do; T Spira; A Lansky; D Ellenberger; R B Lal; C Hyer; R Davis; M Marx; S Paul; J Kent; R Armor; J McFarland; J Lafontaine; S Mottice; S A Cassol; N Michael
Journal:  AIDS       Date:  1999-01-14       Impact factor: 4.177

5.  HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.

Authors:  J Tang; C Costello; I P Keet; C Rivers; S Leblanc; E Karita; S Allen; R A Kaslow
Journal:  AIDS Res Hum Retroviruses       Date:  1999-03-01       Impact factor: 2.205

6.  Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons.

Authors:  D L Ellenberger; P S Sullivan; J Dorn; C Schable; T J Spira; T M Folks; R B Lal
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

7.  CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria.

Authors:  Jean-Pierre Van Geertruyden; Modest Mulenga; Webster Kasongo; Katja Polman; Robert Colebunders; Luc Kestens; Umberto D'Alessandro
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

8.  Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Authors:  Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

9.  A seronegative case of HIV-1 subtype C infection in Botswana.

Authors:  Vladimir Novitsky; Tendani Gaolathe; Elias Woldegabriel; Joseph Makhema; M Essex
Journal:  Clin Infect Dis       Date:  2007-07-20       Impact factor: 9.079

Review 10.  The immune response during acute HIV-1 infection: clues for vaccine development.

Authors:  Andrew J McMichael; Persephone Borrow; Georgia D Tomaras; Nilu Goonetilleke; Barton F Haynes
Journal:  Nat Rev Immunol       Date:  2009-12-11       Impact factor: 53.106

View more
  1 in total

1.  HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic.

Authors:  Romina Cabrera-Rodríguez; Veronique Hebmann; Silvia Marfil; María Pernas; Sara Marrero-Hernández; Cecilia Cabrera; Victor Urrea; Concepción Casado; Isabel Olivares; Daniel Márquez-Arce; Silvia Pérez-Yanes; Judith Estévez-Herrera; Bonaventura Clotet; Lucile Espert; Cecilio López-Galíndez; Martine Biard-Piechaczyk; Agustín Valenzuela-Fernández; Julià Blanco
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.